Investing.com — Processa Pharmaceuticals Inc. (PCSA)股价已跌至52周新低，触及$0.36。这一显著下跌反映了公司正经历艰难时期，过去一年股价暴跌了-84.39%。根据 InvestingPro 数据，公司市值已萎缩至仅220万美元，而在过去十二个月中录得负EBITDA为-1205万美元。投资者一直密切关注公司表现，这一新低点标志着对其未来前景和市 ...

Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.74) EPS for the quarter, beating analysts ...

Processa Pharmaceuticals, Inc. HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy ...

After hours: March 26 at 4:17:26 p.m. EDT Loading Chart for PCSA ...

H.C. Wainwright has adjusted its outlook on Processa Pharmaceuticals (NASDAQ: PCSA), reducing the 12-month price target to $6.00 ...

HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next ...

Processa Pharmaceuticals has a one year low of $0.40 and a one year high of $3.31. The company has a market capitalization of $1.39 million, a price-to-earnings ratio of -0.13 and a beta of 0.75 ...